BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND ITS USE Russian patent published in 2023 - IPC C07D403/12 C07D413/12 C07D417/04 C07D498/04 C07D513/04 C07D519/00 A61K31/551 A61K31/553 A61P29/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound having formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, which has RIP-1 kinase inhibitory activity. In formula (I), T₁ is selected from N and CR_1t; T₂ is selected from N and CR_2t; T₃ is CR_3t; T₄ is CR_4t; E₁ is selected from C(R_1e)₂ and O; cycle A is selected from 1,2,4-triazolyl, where 1,2,4-triazolyl, optionally substituted with 1, 2 or 3 halogens or C_1-3 alkyls; cycle B is selected from phenyl and L is selected from a single bond, O and C_1-3 alkylene; R₁ is selected from H and C_1-3 alkyl, where C_1-3 alkyl is optionally substituted with 1, 2 or 3 R_b substituents; R_1t, R_2t, R_3t and R_4t are each independently selected from H, F, Cl, Br, I, CN, C_1-3 alkyl, COOH and -C(=O)NH₂; R_1e is each independently selected from H and C_1-3 alkyl; R₂ is each independently selected from H, F, Cl, Br, I, CN, C_1-3 alkyl and C_1-3 alkoxy, where C_1-3 alkyl and C_1-3 alkoxy are optionally substituted with 1, 2 or 3 substituents R_f; n is 1, 2, 3, 4 or 5; R_b and R_f are each independently selected from F, Cl, Br, I and D. The invention also relates to particular compounds and to the use of the said compounds in the manufacture of a medicinal product for the treatment of a disease associated with RIP-1 kinase.

EFFECT: obtaining bicyclic compound as RIP-1 kinase inhibitor.

16 cl, 8 tbl, 42 ex